Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02ZUO
|
|||
| Former ID |
DCL000117
|
|||
| Drug Name |
Forodesine
|
|||
| Synonyms |
Immucillin H; Fodosine; Immucillin-H; 209799-67-7; BCX-1777; 1,4-dideoxy-4-aza-1-(s)-(9-deazahypoxanthin-9-yl)-d-ribitol; UNII-426X066ELK; CHEMBL218291; CHEBI:43362; 426X066ELK; (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitol; IMH; 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; (2R,3R,4S,5S)-2-(hydroxymethyl)-5-(4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidine-3,4-diol; Fodosine (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3; ICD-10: C91, C91.9] | Phase 1/2 | [1], [2] | |
| Cutaneous T-cell lymphoma [ICD-11: 2B01; ICD-10: C84.0] | Phase 1/2 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
BioCryst Pharma.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H14N4O4
|
|||
| Canonical SMILES |
C1=C(C2=C(N1)C(=O)NC=N2)C3C(C(C(N3)CO)O)O
|
|||
| InChI |
1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1
|
|||
| InChIKey |
IWKXDMQDITUYRK-KUBHLMPHSA-N
|
|||
| CAS Number |
CAS 209799-67-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
820339, 824927, 829471, 854455, 854458, 7888374, 11532495, 14774821, 15392822, 24770619, 24770621, 24770665, 36887500, 46391523, 46391948, 46392657, 46394112, 46394113, 46530883, 47208247, 49689710, 57404625, 77434485, 85856193, 103500429, 104077585, 104632275, 117682608, 134338803, 134339052, 134340118, 135020342, 135675084, 137042995, 141755560, 144080329, 160644592, 160779316, 165245606, 180372225, 186024301, 198952847, 224718993, 226820362, 241051921, 243906436, 252166484
|
|||
| ChEBI ID |
CHEBI:43362
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8272). | |||
| REF 2 | Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61. | |||
| REF 3 | Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 an... Blood. 2009 Aug 20;114(8):1563-75. | |||
| REF 4 | Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part I. Bioorg Med Chem Lett. 2009 May 15;19(10):2624-6. | |||
| REF 5 | Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma. 2008 Dec;8 Suppl 5:S187-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.